Introduction to management of obsessive-compulsive disorder
===========================================================

Characterized by obsessions, compulsions, considerable functional impairment, and once thought to be quite rare ([@b1-ndt-3-455]), obsessive-compulsive disorder (OCD) may occur in up to approximately 2.4% of the population in North America ([@b27-ndt-3-455]) and typically presents in a person's early 20s ([@b1-ndt-3-455]). For many patients, OCD tends to be chronic, with many people experiencing features of OCD over decades ([@b45-ndt-3-455]). People with OCD also suffer from a lower quality of life compared with healthy controls ([@b37-ndt-3-455]). Both psychotherapeutic and psychopharmacological approaches either singly or together are used in the treatment of OCD. The relationship between treatment response and quality of life in people with OCD is not entirely clear, but some data suggest that quality of life improves with treatment response ([@b37-ndt-3-455]).

Initially consisting of psychoanalysis, psychotherapy for OCD now uses the more effective exposure and response prevention techniques, cognitive therapy, or thought-stopping approaches ([@b1-ndt-3-455]). It is unknown, however, whether exposure and response prevention approaches and cognitive therapy work through separate mechanisms or via common factors, although [@b1-ndt-3-455] concluded that these two therapies work through a similar mechanism due to lack of a differential response between cognitive and physiological features of OCD. Nevertheless, exposure and response prevention treatment not only appears helpful in the short-term treatment of OCD, but also seems to be associated with lower relapse rates compared with pharmacological interventions even after discontinuation ([@b44-ndt-3-455]).

Until the availability of the tricyclic antidepressant clomipramine, pharmacotherapy resulted in little, if any, improvement in OCD. The efficacy of clomipramine in OCD is now well established ([@b15-ndt-3-455]), and its inhibition of serotonin reuptake guided attention to a possible role for serotonin in OCD ([@b1-ndt-3-455]). In fact, non-serotonergic antidepressants appear to have little efficacy in OCD ([@b18-ndt-3-455]; [@b15-ndt-3-455]). Since the introduction of clomipramine, other pharmacological approaches to treat OCD using medication have developed that predominantly include the use of selective serotonin reuptake inhibitors (SSRIs; [@b46-ndt-3-455]). A 1997 meta-analysis comparing clomipramine with fluoxetine and sertraline found larger effect sizes for clomipramine; however, there were relatively few studies of fluoxetine and sertraline, and a large contrast in side effect profiles between clomipramine and placebo may have inflated the effect size for clomipramine ([@b1-ndt-3-455]). More recently, other work also has found that clomipramine tends to be slightly superior to other SSRIs in OCD ([@b2-ndt-3-455]; [@b15-ndt-3-455]). Using meta-regression to control for factors such as clinical-trial length and OCD severity in their meta-analysis of placebo-controlled trials of clomipramine, fluvoxamine, sertraline, and paroxetine, [@b2-ndt-3-455] found superiority for clomipramine. Monoamine oxidase inhibitors may have limited efficacy in OCD and a controlled, 6-week trial of buspirone suggested efficacy in OCD ([@b18-ndt-3-455]). In a double-blind, placebo-controlled, multiple-crossover trial comparing clomipramine, clonazepam, and clonidine against each other in 6-week-long trials for the treatment of OCD, both clomipramine and clonazepam were effective in reducing symptoms ([@b21-ndt-3-455]).

Generally, SSRIs antidepressants tend to be preferred over tricyclic antidepressants in treating anxiety disorders including OCD ([@b44-ndt-3-455]), a practice due to, in part, overall fewer side effects from SSRIs ([@b46-ndt-3-455]). In placebo-controlled trials, citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline all appear effective in the short-term treatment of OCD ([@b18-ndt-3-455]; [@b17-ndt-3-455]), and the SSRIs as a class are generally considered to be first-line drug treatment for OCD ([@b26-ndt-3-455]; [@b44-ndt-3-455]; [@b47-ndt-3-455]), despite the slight possible superiority of clomipramine in efficacy studies ([@b15-ndt-3-455]). Case reports, open trials, and blinded trials comparing venlafaxine with active comparators preliminarily support the efficacy of venlafaxine ([@b40-ndt-3-455]), a dual serotonin and norepinephrine reuptake inhibitor, for OCD. However, a placebo-controlled trial of venlafaxine in OCD did not show clear superiority for venlafaxine ([@b40-ndt-3-455]). As such, more controlled trials are required to establish the place of venlafaxine in the treatment of OCD ([@b15-ndt-3-455]).

Even with the efficacy of behavioral interventions and SSRIs, many patients with OCD continue to have OCD features ([@b18-ndt-3-455]; [@b17-ndt-3-455]). Furthermore, OCD treatment outcome data for over a year are limited ([@b17-ndt-3-455]). To successfully treat OCD, long-term treatment appears to be required due to the chronic nature of OCD. For example, [@b44-ndt-3-455] in a randomized trial investigated relapse rates after treatment discontinuation in patients who had responded to exposure and response therapy alone, to exposure and response therapy plus clomipramine, to clomipramine alone, and to placebo. They found a significant advantage at 12 weeks after treatment discontinuation for patients who had initially responded to exposure and response prevention alone or with clomipramine compared with clomipramine alone. In other words, successful drug treatment for OCD for many patients may require long-term treatment. Moreover, despite the use of SSRIs and psychotherapy, refractory OCD remains a particular challenge ([@b33-ndt-3-455]), resulting in several augmentation strategies.

One approach to managing treatment-resistant OCD is adding drugs that increase serotonin transmission to SSRIs ([@b32-ndt-3-455]). Clomipramine, for instance, has been combined with SSRIs, although this combination is poorly studied and requires careful monitoring of plasma clomipramine and desmethylclomipramine levels ([@b18-ndt-3-455]). Drugs in addition to clomipramine have been added to SSRIs in refractory cases. However, a double-blind trial found little advantage using lithium to augment fluvoxamine in treatment-resistant OCD ([@b35-ndt-3-455]). Similarly, [@b33-ndt-3-455] in a placebo-controlled trial found little advantage when buspirone was added to fluvoxamine in patients who had not responded to fluvoxamine alone. Other drugs that have been combined with an SSRI in an attempt to improve response in OCD include donepezil and gabapentin ([@b18-ndt-3-455]), although these trials tended to be small and uncontrolled. The double-blind, placebo-controlled addition of the beta blocker pindolol to patients who had not responded to open treatment with paroxetine resulted in improvement as measured by the Yale-Brown Obsessive-Compulsive Scale ([@b12-ndt-3-455]). In contrast, an earlier double-blind, placebo-controlled trial of pindolol or placebo in conjunction with fluvoxamine showed no differences between groups ([@b38-ndt-3-455]).

A second approach to treatment refractory OCD outlined by [@b32-ndt-3-455] includes the use of low-dose dopamine antagonists added to existing regimens of SSRIs. Second-generation antipsychotics, for example, may improve the treatment response when added to an SSRI that is only producing a partially favorable response ([@b46-ndt-3-455]). In a double-blind, placebo-controlled trial, [@b32-ndt-3-455] found that low-dose risperidone was effective in reducing OCD features when added to an SSRI. Similarly, in a double-blind, placebo-controlled study of treatment-refractory subjects with OCD already taking fluoxetine, paroxetine, sertraline, or clomipramine, [@b8-ndt-3-455] reported that the addition of the second-generation antipsychotic olanzapine to an SSRI in a double-blind, randomized trial was superior to the placebo group. Some controlled evidence supports the use of intravenous clomipramine for treatment-refractory OCD ([@b18-ndt-3-455]). Finally, in some severe, treatment-refractory cases, stereotactic cingulotomy or other neurosurgical intervention can be associated with improvement in OCD, although these procedures tend to be reserved for extreme cases ([@b10-ndt-3-455]; [@b11-ndt-3-455]; [@b25-ndt-3-455]).

Despite the use of both psychotherapy and pharmacotherapy in OCD, the response to treatment is often suboptimal ([@b33-ndt-3-455]), even with augmentation techniques ([@b8-ndt-3-455]). In fact, according to some estimates, approximately 40% ([@b15-ndt-3-455]) to 60% ([@b18-ndt-3-455]; [@b39-ndt-3-455]) of patients with OCD have an inadequate response to SSRIs. Further, even some reduction in OCD features still may leave patients with considerable morbidity ([@b18-ndt-3-455]). The prevalence of inadequate response to available OCD treatments argues for a need to consider alternative approaches to the management of OCD. One such potential treatment warranting consideration for use in adult OCD is the SSRI escitalopram.

Pharmacology and mechanism of action of escitalopram
====================================================

The SSRI citalopram is a racemic preparation ([@b30-ndt-3-455]) composed of both right (R) and left (S) stereoisomers ([@b7-ndt-3-455]) in a 1:1 ratio ([@b42-ndt-3-455]). However, biochemistry in vivo appears to be enantiomer selective, possibly responding preferentially to only one stereoisomer ([@b7-ndt-3-455]), consistent with findings that it is the S-enantiomer of citalopram (ie, escitalopram) that inhibits serotonin reuptake ([@b23-ndt-3-455]). In fact, citalopram's R-enantiomer appears to be relatively inactive ([@b16-ndt-3-455]). Not only may it be inactive, but findings suggest that the R-enantiomer of citalopram may actually interfere with the action of the S-enantiomer. For example, [@b42-ndt-3-455] reported that R-citalopram significantly interfered with the anxiolytic-like effect of escitalopram in an animal model. The interference effect of R-citalopram may not extend to other SSRIs, as suggested by findings showing that R-citalopram did not appear to inhibit the behavioral effects of fluoxetine ([@b48-ndt-3-455]). However, findings showing that R-citalopram can interfere with S-citalopram provide a rationale for the possibility that S-citalopram could have superior clinical efficacy compared with citalopram, which contains both R and S enantiomers. Moreover, the behavioral effect of escitalopram in the fear conditioned stress animal model of anxiety was greater than the behavioral effect of the dose-equivalent racemic preparation of citalopram, an observation providing additional evidence that the enantiomer specificity of escitalopram carries an advantage over citalopram, even though citalopram contains escitalopram ([@b42-ndt-3-455]). Finally, equivalent doses of escitalopram increase frontal extracellular serotonin more than does citalopram ([@b3-ndt-3-455]).

Used in adults for the treatment of depressive and anxiety disorders ([@b5-ndt-3-455]), the SSRI escitalopram is simply the S-enantiomer of citalopram ([@b7-ndt-3-455]), a development designed to take advantage of physiological stereoisomer specificity by producing a drug preparation consisting of only one stereoisomer.

Like other SSRIs, escitalopram initiates its biological effects by binding to the serotonin transport molecule ([@b5-ndt-3-455]) and increasing the concentration of serotonin in the synapse. A notable feature of escitalopram is that it is the most selective of all the SSRIs, having little or no affinity for 144 other binding sites ([@b42-ndt-3-455]). In addition, escitalopram binds to both the primary, high-affinity site on the serotonin transporter protein, which inhibits serotonin reuptake, and to a low-affinity site that alters binding at the primary site ([@b16-ndt-3-455]). Consistent with findings showing that R-citalopram is relatively inactive ([@b16-ndt-3-455]), escitalopram binds more than 30 times more potently to the serotonin transporter receptor than does R-citalopram ([@b5-ndt-3-455]), providing further support that stereoisomers have biological relevance. Other neurotransmitter receptors may be affected differently by R-citalopram and escitalopram. For example, [@b42-ndt-3-455] reported that citalopram and R-citalopram have affinity for the histamine 1 receptor, whereas escitalopram does not.

It is likely that binding to the serotonin transporter initiates a series of effects in the brain beyond serotonin reuptake inhibition. Although little such data exist for escitalopram, functional neuroimaging data from citalopram are intriguing. In a study using single photon emission computed tomography, [@b9-ndt-3-455] found that citalopram treatment was associated with significant deactivation in the cingulate cortex, right thalamus, and left hippocampus in several anxiety disorders including OCD. Citalopram treatment may affect other metabolic factors in addition to cerebral blood flow. For example, citalopram use in OCD was associated with prefrontal and frontal white matter increases in N-acetylaspartate ([@b24-ndt-3-455]), showing that citalopram can substantially alter brain function in various brain regions. While comparable data for escitalopram are not available, escitalopram may well cause cerebral blood-flow and metabolic effects similar to those reported with citalopram because of the racemic nature of citalopram.

Pharmacokinetics of escitalopram
================================

In general, the pharmacokinetics of escitalopram appear favorable. For instance, the relationship between escitalopram dose and plasma concentrations is linear, which allows for plasma levels to be predicted from dose ([@b5-ndt-3-455]). The absorption of escitalopram is not affected by food, and it reaches peak serum levels in three to four hours ([@b3-ndt-3-455]). The half-life of escitalopram varies from approximately 27 to 32 hours ([@b5-ndt-3-455]), enabling once daily dosing and eliminating the need for multiple daily doses. In people over age 65 though, the half-life can increase to 40 hours ([@b3-ndt-3-455]), necessitating dosage adjustments in the elderly ([@b16-ndt-3-455]). Steady state plasma concentrations in healthy volunteers occur in 7 to 10 days ([@b16-ndt-3-455]). Like all other SSRIs, escitalopram undergoes extensive metabolism by cytochrome P450 enzymes, which convert escitalopram to S-desmethyl-citalopram and then to S-didesmethyl-citalopram ([@b49-ndt-3-455]), neither of which metabolites appear to significantly affect serotonin reuptake ([@b16-ndt-3-455]). An in vitro study found that the cytochrome P450 enzymes 2C19, 2D6, and 3A4 accounted for 37%, 28%, and 35% respectively of the metabolism of escitalopram ([@b49-ndt-3-455]). Drugs that inhibit these enzymes can increase escitalopram concentrations ([@b16-ndt-3-455]). Compared with some other SSRIs, escitalopram may have weak or minimal interactions with the cytochrome P450 system ([@b49-ndt-3-455]; [@b5-ndt-3-455]), reducing the potential for cytochrome P450 drug--drug interactions ([@b49-ndt-3-455]). In vivo work, in contrast, shows that escitalopram can inhibit cytochrome P450 2D6 ([@b16-ndt-3-455]), an effect that requires further study to more fully understand escitalopram's potential for drug-drug interactions.

Escitalopram efficacy studies
=============================

To date, escitalopram has shown efficacy in adult major depression ([@b5-ndt-3-455]; [@b6-ndt-3-455]), a condition in which it may have a faster antidepressant response than citalopram ([@b31-ndt-3-455]). A number of relatively short-term trials have found that escitalopram has efficacy for social anxiety disorder, panic disorder, and generalized anxiety disorder ([@b5-ndt-3-455]). For example, in a double-blind, placebo-controlled trial over 12 and 24 weeks, [@b30-ndt-3-455] found escitalopram to be superior to placebo for the management of social anxiety disorder. Similarly, [@b28-ndt-3-455] found escitalopram in a double-blind, placebo-controlled, randomized trial to be superior to placebo in social anxiety disorder, despite a high placebo response in this study. Investigating generalized social anxiety disorder in a double-blind, placebo-controlled, randomized trial, [@b36-ndt-3-455] found escitalopram to be effective and well tolerated over a 24 week study. Another double-blind, placebo-controlled study also found escitalopram to be effective in generalized anxiety disorder, with discontinuation rates from escitalopram not significantly different from those from placebo ([@b13-ndt-3-455]). In their review of the use of escitalopram for the treatment of generalized anxiety disorder, [@b3-ndt-3-455] note that escitalopram has shown efficacy in generalized anxiety for up to 6 months.

Despite findings that escitalopram appears to have efficacy in several anxiety disorders, little work so far has examined directly the efficacy of escitalopram in OCD. Several case reports suggest that escitalopram may be effective for conditions having either obsessive features or argued by some researchers to be related to OCD ([@b22-ndt-3-455]). For instance, in a case report of a 15-year-old male with transvestic fetishism thought by the authors to have a compulsive quality, the addition of escitalopram resulted in diminished recurrent thoughts ([@b41-ndt-3-455]). Another case report found escitalopram use in a 10-year-old boy to be associated with a reduction of trichotillomania ([@b4-ndt-3-455]), a condition that shares some similarities with OCD and may be part of an obsessive-compulsive spectrum ([@b22-ndt-3-455]). In an open-label trial followed by double-blind discontinuation of pathological gambling with anxiety, escitalopram appeared effective ([@b20-ndt-3-455]). [@b29-ndt-3-455] reported a case of obsessive-compulsive disorder characterized by compulsive vomiting that appeared to respond favorably to escitalopram.

Stein et al (2006) conducted the only reported randomized, double-blind, placebo-controlled trial of escitalopram in OCD, a study that also included the active comparison drug paroxetine. After randomization to fixed doses of escitalopram 10 mg/day (n = 113), escitalopram 20 mg/day (n = 114), paroxetine 40 mg/day (n = 117), or placebo (n = 114) for 24 weeks, no significant differences in drop-out rates were found between the four groups, although fewer people dropped out of the two escitalopram groups compared with those dropping out of the placebo and paroxetine groups. In terms of efficacy, at 12 weeks, the escitalopram 20 mg/day group and paroxetine groups were superior to placebo, and the escitalopram 10 mg/day group was superior to placebo, albeit with a p value of only 0.052. Compared with placebo, week 12 effect sizes were 0.43 and 0.33 for escitalopram 20 mg/day and paroxetine, respectively. By week 24, both escitalopram groups and the paroxetine group were significantly superior to placebo in terms of treatment response rates. An analysis of remission, defined as a score on the Yale-Brown Obsessive-Compulsive Scale of less than or equal to 10, showed that only the escitalopram 20 mg group was reliably better than placebo in direct comparison to paroxetine 40 mg,

Comparing relapse rates in a large, multi-center study in OCD patients who had responded to 16 weeks of open-label treatment with escitalopram followed by randomized, double-blind treatment with either escitalopram (fixed dose of 10 or 20 mg) or placebo for up to an additional 24 weeks, [@b19-ndt-3-455] found that escitalopram doses at 10 and 20 mg daily were superior to placebo in preventing relapse. Drop-out rates not related to relapse were similar between the escitalopram and placebo groups. At the end of the open-label part of the study, the response rate (defined by a decrease in the Yale-Brown Obsessive-Compulsive Scale of greater than or equal to 25%) was 74%.

Escitalopram safety and tolerability
====================================

Both short- and long-term outcome are important when evaluating a drug for OCD ([@b46-ndt-3-455]; [@b19-ndt-3-455]). As such, drug tolerability requires careful consideration when evaluating a drug's role in the treatment of a disorder, particularly a chronic disorder such as OCD that often entails long-term treatment. One method of assessing tolerability is to evaluate discontinuation rates due to adverse effects in clinical trials. On this count, discontinuation from escitalopram in some trials tends to be approximately the same as discontinuation rates from placebo ([@b5-ndt-3-455]; [@b19-ndt-3-455]). Nonetheless, escitalopram is associated with several adverse effects that potentially can decrease a patient's quality of life, including dry mouth, insomnia, difficulty with ejaculation, nausea, diarrhea, drowsiness ([@b5-ndt-3-455]), yawning ([@b30-ndt-3-455]), fatigue, headache, dizziness, and increased sweating ([@b36-ndt-3-455]).

[@b36-ndt-3-455] found more adverse effects early in their study of escitalopram for generalized social anxiety disorder than later in the study, implying the possibility that tolerance may occur to escitalopram's adverse effects. Furthermore, when these authors excluded adverse-effect data from the first two weeks of their study, they found that adverse effects were similar overall in the escitalopram and placebo groups.

Analyzing data for escitalopram tolerability in generalized anxiety disorder over six months of treatment ([@b13-ndt-3-455]), [@b3-ndt-3-455] found that the most commonly reported adverse effects were headache (25.5%), ejaculation disorder (16%), upper respiratory tract infection (15.4%), nausea (15.2%), and insomnia (14.8%). [@b3-ndt-3-455] concluded that in generalized anxiety disorder, escitalopram was better tolerated overall than paroxetine. Finally, withdrawal from escitalopram appears to be less severe than withdrawal from paroxetine ([@b36-ndt-3-455]).

Conclusion -- role of escitalopram in OCD
=========================================

Based on currently available findings, few studies have evaluated the use of escitalopram in OCD and only one placebo-controlled, randomized study was conducted, limiting the conclusions that can be drawn about the efficacy of escitalopram in OCD. Several factors, however, suggest that escitalopram may have considerable clinical potential in the treatment of adult OCD. First, it is an SSRI, like other drugs that are considered to be first-line drug treatments for OCD ([@b17-ndt-3-455]). Second, escitalopram may possess unique advantages compared with other SSRIs in that it consists of not a racemic mixture but rather only the S isomer, a preparation that may target the organization of the nervous system more specifically than a racemic mixture. Third, escitalopram is the most selective of the SSRIs ([@b42-ndt-3-455]). Fourth, escitalopram has shown efficacy in other anxiety disorders including social anxiety disorder, panic disorder, and generalized anxiety disorder ([@b16-ndt-3-455]). More importantly, the one well-designed, double-blind, placebo-controlled trial to date of escitalopram in OCD ([@b47-ndt-3-455]) found that escitalopram was superior to placebo for the treatment of OCD. Finally, the evidence to date suggests that escitalopram is reasonably well tolerated and has favorable pharmacokinetics, important features for a drug used to treat a highly chronic condition. Nonetheless, given the few randomized, placebo-controlled trials of escitalopram for OCD to date, the role of escitalopram in the treatment of this condition will be better defined by data from additional controlled trials. Clearly, more clinical data are needed before the role of escitalopram in OCD can be defined. In addition to its clinical potential for the treatment of OCD, escitalopram may offer theoretical insight into the role of stereo-specific enantiomers in OCD. Together, these factors provide a rationale for additional trials of escitalopram in OCD. To further understand the role of escitalopram in the treatment of OCD, more data are required to evaluate its use with behavioral interventions such as exposure and response prevention treatment. Of equal importance is a better understanding of the role of escitalopram in the long-term treatment of OCD.
